seen as an anticipated newsflow/milestone dated for Q2 2021, I would like to see an ann that this toxicology study has indeed been initiated. n They tend to bring out an ann after the fact and luckily thus far all positive.
Hope we do not have to wait much longer for some information around this
Would commencement of these tox studies require PET to ann this as part of regulatory continuous disclosure????
Ann: Full size deoxymab PAT-DX3 crosses the blood brain barrier, page-81
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $73.58K | 18.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 16801257 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7789761 | 11 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |